HLA-DQA105 and upstream variants of PPARGC1B are associated with infliximab persistence in Japanese Crohn's disease patients

Recently, the HLA-DQA1*05 (rs2097432) genetic variation has been reported to be linked to early infliximab (IFX) treatment failure in the Caucasian Crohn's disease (CD) population, but that evidence is scarce in the Asian population. This study aimed to investigate the relationship between rs20...

Full description

Saved in:
Bibliographic Details
Published inThe pharmacogenomics journal Vol. 23; no. 6; pp. 141 - 148
Main Authors Shimoda, Fumiko, Naito, Takeo, Kakuta, Yoichi, Kawai, Yosuke, Tokunaga, Katsushi, Shimoyama, Yusuke, Moroi, Rintaro, Shiga, Hisashi, Nagasaki, Masao, Kinouchi, Yoshitaka, Masamune, Atsushi
Format Journal Article
LanguageEnglish
Published United States Nature Publishing Group 01.11.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Recently, the HLA-DQA1*05 (rs2097432) genetic variation has been reported to be linked to early infliximab (IFX) treatment failure in the Caucasian Crohn's disease (CD) population, but that evidence is scarce in the Asian population. This study aimed to investigate the relationship between rs2097432 and the cumulative discontinuation-free time of IFX (IFX persistence) in 189 Japanese biologics-naive CD patients. We also performed a genome-wide association study (GWAS) to discover novel genetic predictors for IFX persistence. The C allele of rs2097432 significantly increased the risk of early discontinuation of IFX [Hazard ratio (HR) = 2.23 and P-value = 0.026]. In GWAS, one locus tagged by rs73277969, located upstream of PPARGC1B which attenuates macrophage-mediated inflammation, reached genome-wide significance (HR = 6.04 and P-value = 7.93E-9). Pathway analysis suggested association of signaling by PDGF and FCGR activation signaling with IFX persistence (P-value = 8.56E-5 and 5.80E-4, respectively).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1470-269X
1473-1150
DOI:10.1038/s41397-023-00312-z